BioSpace News Archive

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2022 after the close of trading on Tuesday, November 8, 2022.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the 7D FLASH™ Navigation System Percutaneous Spine Module.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after market close.

Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan.

Origin Therapeutics Holdings Inc.(CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”) today announced that one of its portfolio companies, Clairvoyant Therapeutics (“Clairvoyant”), has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland.

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming investor conferences.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended September 30, 2022 after the close of the market on Thursday, November 3, 2022.

Berkeley Lights, Inc., a leader in digital cell biology, announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022.

Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022.

Denali Therapeutics Inc. announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering.